evalu
efficaci
three
sar
vaccin
candid
murin
sar
model
util
lowvirul
pp
sarscov
coinfect
vaccin
mice
protect
sever
respiratori
diseas
parallel
low
viru
titer
lung
high
neutral
antibodi
titer
plasma
importantli
administr
spike
proteinspecif
neutral
monoclon
antibodi
protect
mice
diseas
indic
neutral
suffici
protect
moreov
high
level
product
cytokin
test
day
sarscov
infect
close
link
viru
replic
diseas
sever
suggest
import
cytokin
lung
pathogen
sarscov
infect
mous
respiratori
tract
mani
vaccin
studi
sarscov
identifi
protein
among
sarscov
structur
protein
major
determin
neutral
develop
anim
model
crucial
evalu
vaccin
efficaci
sarscovinduc
lung
pathogenes
sarscov
infect
occur
transient
mous
viru
clear
day
postinfect
although
agerel
suscept
lung
diseas
old
mice
shown
cours
studi
cell
entri
mechan
sarscov
found
proteas
trypsin
elastas
produc
host
anim
enhanc
sarscov
infect
cultur
cell
previou
studi
examin
whether
weak
inflamm
lung
induc
lowpathogen
bacteri
infect
could
induc
elastas
enhanc
sarscov
infect
show
lowvirul
c
societi
blackwel
publish
asia
pti
ltd
pp
infect
well
administr
lipopolysaccharid
deriv
escherichia
coli
induc
elastas
lung
enhanc
replic
sarscov
result
exacerb
respiratori
diseas
caus
sarscov
infect
high
mortal
rate
result
indic
coinfect
sarscov
lowvirul
microorgan
induc
exacerb
pneumonia
suggest
possibl
elastas
involv
pathogenesi
exacerb
pneumonia
caus
sarscov
infect
research
group
uvinactiv
uvand
formalininactiv
whole
virion
vaccin
produc
shown
effect
elicit
persist
neutral
antibodi
accompani
tcell
respons
also
construct
replicationdefici
recombin
vaccinia
viru
di
express
one
sarscov
structur
protein
e
n
combin
e
em
e
n
emn
recombin
di
vaccin
given
mice
either
sc
intranas
humor
cellular
immun
sarscov
elicit
show
high
level
serum
neutral
igg
antibodi
elicit
subcutan
inject
vaccinia
strongli
suppress
sarscov
replic
lung
neutral
igatyp
antibodi
elicit
mucos
intranas
immun
absolut
requir
furthermor
demonstr
di
express
protein
alon
combin
compon
n
alon
elicit
strong
neutral
antibodi
tcell
respons
sarscov
infect
although
other
demonstr
vaccin
express
protein
alon
abl
inhibit
sarscov
replic
effici
mice
role
nspecif
tcell
respons
protect
formal
exclud
sarscov
infect
mice
usual
clear
rapidli
without
caus
pulmonari
diseas
util
murin
model
system
sever
respiratori
diseas
caus
coinfect
pp
sarscov
evalu
protect
efficaci
sar
vaccin
candid
uvor
uvplusformalininactiv
whole
virion
recombin
di
express
protein
monitor
bodyweight
analyz
viru
replic
cytokin
product
lung
lavag
vaccin
mice
sarscov
infect
give
monoclon
neutral
antibodi
recogn
protein
pp
infect
mortal
mice
coinfect
pp
sarscov
dramat
reduc
dosedepend
manner
result
clearli
show
neutral
antibodi
protein
highli
effect
suffici
prevent
sar
develop
furthermor
found
product
associ
high
titer
sarscov
suggest
possibl
link
increas
product
cytokin
lung
pathogen
caus
pp
sarscov
coinfect
frmo
mouseadapt
strain
creat
passag
time
mice
final
grown
cell
propag
plaqu
assay
cell
previous
describ
cell
grown
maintain
dulbecco
modifi
minim
essenti
medium
dmem
nissui
tokyo
japan
viru
infect
determin
plaqu
assay
previous
describ
uvinactiv
purifi
sarscov
uvv
prepar
previous
describ
brief
sarscov
amplifi
vero
cell
expos
uv
light
jcm
purifi
sucros
densiti
gradient
centrifug
portion
uvinactiv
purifi
virion
treat
overnight
formalin
uvfv
assur
safeti
whole
virion
vaccin
anim
studi
carri
protocol
approv
anim
care
use
committe
nation
institut
infecti
diseas
japan
sixweekold
balbc
male
mice
purchas
slc
hamamatsu
japan
charl
river
japan
crj
tokyo
japan
mice
serolog
check
free
infect
pathogen
microorgan
includ
pp
vaccin
recombin
di
mice
sc
immun
plaqueform
unit
pfu
rdissarss
di
neg
control
week
ident
titer
virus
readminist
vaccin
whole
inactiv
virion
mice
sc
inject
back
uvv
uvfv
mg
alum
boost
procedur
week
prime
one
week
later
mice
anesthet
xylazin
ketamin
intraperiton
ip
administr
intranas
inocul
colonyform
unit
cfu
pp
mam
strain
suspend
pb
kept
globe
box
isol
bsl
laboratori
institut
experiment
period
one
day
later
mice
intranas
challeng
tcid
sarscov
salin
previous
describ
three
day
challeng
sarscov
serum
nasal
lung
lavag
fluid
collect
measur
viral
titer
antibodi
sarscov
mice
kill
anesthesia
chloroform
bodyweight
mice
measur
everi
day
igg
titer
sarscov
determin
elisa
previous
describ
neutral
antibodi
titer
determin
previous
describ
briefli
sampl
heatinactiv
dilut
twofold
dmem
contain
fetal
bovin
serum
infecti
unit
vesicular
stomat
viru
vsv
pseudotypebear
sarscov
protein
mixtur
incub
hr
c
neutral
incub
mixtur
inocul
onto
vero
cell
seed
plate
infect
determin
count
number
green
fluoresc
protein
gfp
posit
cell
nab
titer
defin
reciproc
highest
dilut
inhibit
infect
observ
cytokin
chemokin
assay
either
use
mous
inflammatori
cytokin
cytometr
bead
array
kit
becton
dickinson
san
jose
ca
usa
use
luminex
system
luminex
co
austin
tx
usa
previous
report
lung
homogen
prepar
describ
dilut
lysi
buffer
virus
includ
materi
complet
inactiv
uv
irradi
min
luminex
system
follow
cytokin
chemokin
measur
mous
cytokin
plex
antibodi
bead
kit
bioscienc
intern
inc
camarillo
ca
usa
fibroblast
growth
factor
basic
granulocytemacrophag
colonystimul
factor
keratinocytederiv
chemokin
kc
monokineinduc
ifninduc
protein
ip
vascular
endotheli
growth
factor
vegf
studi
sar
vaccin
efficaci
use
recent
establish
murin
sar
model
model
lowvirul
pp
infect
exacerb
lung
pathogenesi
associ
sarscov
infect
first
examin
protect
efficaci
uvand
uvplusformalininactiv
whole
virion
uvv
uvfv
respect
twelv
mice
group
sc
inocul
uvv
uvfv
alum
alum
pb
alum
control
booster
immun
vaccin
week
infect
pp
intranas
week
later
one
day
infect
pp
mice
intranas
infect
mouseadapt
strain
sarscov
frmo
although
pp
low
virul
caus
mild
respiratori
diseas
ppinfect
mice
show
transient
loss
bodyweight
ruffl
hair
day
postinfect
gradual
recov
howev
mice
coinfect
sarscov
day
pp
infect
sever
weight
loss
show
high
mortal
exacerb
pneumonia
murin
model
sar
control
uvvor
uvfvvaccin
mice
show
transient
decreas
bodyweight
day
sarscov
infect
fig
vaccin
mice
recov
origin
weight
sarscov
infect
wherea
control
mice
alum
continu
lost
weight
die
day
postinfect
second
set
experi
mice
immun
recombin
diss
empti
di
neg
control
discont
week
week
pp
infect
infect
sarscov
next
day
similar
result
whole
virion
vaccin
describ
mice
vaccin
di
show
transient
minim
clinic
symptom
ruffl
hair
weight
loss
day
frmo
infect
fig
left
sever
symptom
continu
observ
period
control
mice
day
viru
infect
mice
suffer
loss
bodyweight
mice
die
exhibit
sever
respiratori
diseas
wherea
none
mice
vaccin
recombin
di
express
protein
die
fig
right
evalu
vaccin
effect
measur
serum
neutral
antibodi
sarscov
titer
lung
lavag
vaccin
mice
pp
sarscov
coinfect
vaccin
mice
develop
high
level
antisarscov
igg
neutral
activ
data
shown
shown
figur
high
level
neutral
antibodi
maintain
coinfect
experi
day
day
postinfect
vaccin
mous
group
sarscov
titer
lung
lavag
high
day
postinfect
decreas
day
fig
blank
column
alum
discont
viru
becam
undetect
day
data
shown
contrast
viru
titer
significantli
reduc
parallel
high
titer
plasma
neutral
antibodi
vaccin
group
fig
therefor
whole
virion
vaccin
vaccinia
vector
express
spike
protein
protect
highli
pathogen
pulmonari
infect
sarscov
presenc
opportunist
infect
pp
case
furthermor
result
diss
vaccin
suggest
neutral
antibodi
sarscov
spike
protein
alon
highli
effect
prevent
sar
develop
ami
et
al
demonstr
previous
level
significantli
high
sarscovinfect
ppsarscovcoinfect
mous
lung
homogen
day
sarscov
infect
howev
cytokin
becam
undetect
day
postinfect
better
understand
involv
cytokin
lung
pathogenesi
sar
simultan
measur
six
cytokin
lung
lavag
vaccin
unvaccin
mice
day
sarscov
infect
virus
replic
extens
vaccin
mice
experienc
maximum
weight
loss
shown
figur
increas
product
lung
control
mous
group
alum
discont
strongli
suppress
vaccin
mice
abl
control
viru
replic
increas
product
cytokin
includ
observ
therefor
possibl
play
role
establish
lung
patholog
pp
sarscov
coinfect
model
known
mani
neutral
antibodi
sarscov
recogn
receptorbind
domain
rbd
spike
protein
although
ntermin
domain
domain
also
neutral
epitop
previous
establish
four
sproteinspecif
monoclon
antibodi
potent
vitro
neutral
activ
among
major
epitop
local
rbd
protein
exhibit
potent
neutral
activ
demonstr
antispik
neutral
antibodi
mainli
respons
protect
efficaci
observ
sar
model
mice
administ
ip
pp
infect
shown
figur
mice
treat
recov
loss
bodyweight
resist
fatal
outcom
observ
vaccin
mice
measur
viru
titer
lung
lavag
day
sarscov
infect
dramat
decreas
accord
concentr
neutral
antibodi
given
fig
level
serum
neutral
antibodi
mice
proport
high
time
point
neutral
activ
low
still
detect
lung
lavag
result
clearli
show
neutral
antibodi
protein
highli
effect
prevent
sar
develop
observ
high
level
product
pp
sarscovcoinfect
mous
lung
lavag
day
sarscov
infect
fig
howev
cytokin
profil
mice
may
variabl
modifi
pp
infect
alon
sarscov
infect
therefor
measur
cytokin
lung
lavag
protect
unprotect
mice
use
mous
cytokin
antibodi
bead
kit
day
pp
infect
sarscov
infect
day
day
day
sarscov
infect
previous
report
product
two
cytokin
increas
day
sarscov
infect
associ
high
titer
sarscov
shown
figur
interestingli
product
increas
pp
infect
alon
decreas
day
increas
wherea
increas
sarscov
infect
cytokin
increas
protect
mice
fig
suggest
import
two
cytokin
lung
pathogenesi
cytokin
profil
shown
figur
c
level
quit
high
sarscov
infect
day
howev
even
protect
mice
produc
high
level
contrast
macrophag
inflammatori
protein
mip
kc
produc
sarscov
infect
level
vegf
consist
low
concentr
cytokin
low
limit
detect
data
shown
result
suggest
play
role
lung
pathogen
pp
sarscov
coinfect
present
studi
evalu
protect
efficaci
sar
vaccin
candid
uvor
uvplusformalininactiv
whole
virion
recombin
di
express
protein
diss
use
murin
model
system
sever
respiratori
diseas
caus
coinfect
pp
sarscov
result
shown
paper
suggest
whole
virion
vaccin
either
without
formalin
treatment
diss
protect
c
societi
blackwel
publish
asia
pti
ltd
highli
pathogen
pulmonari
infect
sarscov
presenc
opportunist
infect
pp
give
sarscov
infect
mortal
mice
coinfect
pp
sarscov
dramat
reduc
level
serum
neutral
antibodi
mice
proport
high
viru
titer
lung
lavag
sarscov
infect
substanti
decreas
accord
concentr
neutral
antibodi
given
therefor
high
titer
neutral
igg
antibodi
protein
system
elicit
vaccin
would
suffici
prevent
sar
develop
treatment
convalesc
plasma
success
use
treat
sar
suggest
passiv
immun
might
use
approach
combat
sar
antibodi
shown
neutral
viru
vitro
prevent
viral
replic
mous
model
sarscov
infect
sui
et
al
investig
antivir
activ
human
monoclon
antibodi
protein
block
receptor
associ
demonstr
prophylact
effect
monoclon
antibodi
vivo
use
mous
model
sar
recent
sever
human
monoclon
antibodi
protein
develop
therapeut
applic
mani
neutral
antibodi
sarscov
recogn
rbd
spike
protein
ntermin
domain
domain
also
neutral
epitop
passiv
immun
highli
effect
combin
neutral
antibodi
recogn
sever
epitop
protein
design
viru
escap
mutat
prevent
involv
cytokin
sar
pathogenesi
describ
level
variou
cytokin
chemokin
lung
mice
infect
pp
sarscov
measur
high
level
product
note
day
follow
coinfect
day
therefor
involv
cytokin
high
pathogenesi
caus
coinfect
pp
sar
cov
suggest
studi
observ
product
increas
day
sarscov
infect
associ
high
titer
sarscov
wherea
cytokin
increas
vaccineprotect
mice
therefor
analyz
kinet
multipl
cytokin
chemokin
product
detail
pp
pp
sarscov
coinfect
vaccin
mice
although
sever
cytokin
chemokin
ubiquit
temporarili
upregul
lung
inflamm
caus
microb
found
level
profil
product
well
match
diseas
sever
protect
contribut
inflammatori
cytokin
sar
human
need
investig
